Total Payments
$33,869
2024 Payments
$999.41
Companies
33
Transactions
426
Medicare Patients
2,706
Medicare Billing
$271,171
Payment Breakdown by Category
Food & Beverage$10,651 (31.4%)
Other$10,547 (31.1%)
Research$8,000 (23.6%)
Consulting$4,550 (13.4%)
Education$102.85 (0.3%)
Travel$18.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,651 | 414 | 31.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,547 | 6 | 31.1% |
| Unspecified | $8,000 | 1 | 23.6% |
| Consulting Fee | $4,550 | 2 | 13.4% |
| Education | $102.85 | 2 | 0.3% |
| Travel and Lodging | $18.00 | 1 | 0.1% |
Payments by Type
General
$25,869
425 transactions
Research
$8,000
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $12,215 | 140 | $0 (2024) |
| Eli Lilly and Company | $8,000 | 1 | $0 (2020) |
| Gilead Sciences, Inc. | $4,084 | 46 | $0 (2024) |
| FUJIFILM Medical Systems USA, Inc. | $2,110 | 1 | $0 (2017) |
| Mallinckrodt Hospital Products Inc. | $2,000 | 1 | $0 (2020) |
| Janssen Biotech, Inc. | $620.28 | 25 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $573.23 | 26 | $0 (2023) |
| Intercept Pharmaceuticals, Inc. | $555.26 | 21 | $0 (2024) |
| PFIZER INC. | $508.14 | 22 | $0 (2022) |
| Merck Sharp & Dohme LLC | $476.01 | 22 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $999.41 | 43 | ABBVIE INC. ($369.47) |
| 2023 | $896.62 | 37 | AbbVie Inc. ($547.56) |
| 2022 | $1,106 | 49 | ABBVIE INC. ($441.40) |
| 2021 | $1,388 | 57 | AbbVie Inc. ($258.63) |
| 2020 | $10,783 | 34 | Eli Lilly and Company ($8,000) |
| 2019 | $4,262 | 77 | Gilead Sciences, Inc. ($2,911) |
| 2018 | $8,676 | 74 | AbbVie, Inc. ($7,405) |
| 2017 | $5,759 | 55 | AbbVie, Inc. ($2,652) |
All Payment Transactions
426 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $20.24 | General |
| Category: LIVER DISEASE | ||||||
| 11/20/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $13.92 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 11/13/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $24.61 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/06/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $21.25 | General |
| 11/01/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: Immunology | ||||||
| 10/28/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $23.21 | General |
| Category: IMMUNOLOGY | ||||||
| 10/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $133.25 | General |
| 10/04/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: LIVER DISEASE | ||||||
| 09/30/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 09/20/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: IMMUNOLOGY | ||||||
| 09/13/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $28.27 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/11/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $23.21 | General |
| Category: Neuroscience | ||||||
| 09/09/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.16 | General |
| 09/06/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $32.46 | General |
| Category: IMMUNOLOGY | ||||||
| 08/26/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $14.76 | General |
| Category: IMMUNOLOGY | ||||||
| 08/23/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $12.08 | General |
| Category: VIROLOGY | ||||||
| 08/14/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.52 | General |
| Category: IMMUNOLOGY | ||||||
| 08/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $12.22 | General |
| Category: INTERNAL MEDICINE | ||||||
| 07/26/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $21.32 | General |
| Category: INTERNAL MEDICINE | ||||||
| 07/19/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: VIROLOGY | ||||||
| 07/10/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $31.80 | General |
| Category: IMMUNOLOGY | ||||||
| 06/12/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 06/07/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: IMMUNOLOGY | ||||||
| 06/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $20.24 | General |
| Category: INTERNAL MEDICINE | ||||||
| 05/22/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $27.32 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | Eli Lilly and Company | $8,000 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 551 | 656 | $405,215 | $57,303 |
| 2022 | 14 | 730 | 830 | $385,170 | $67,506 |
| 2021 | 16 | 764 | 969 | $429,595 | $75,350 |
| 2020 | 15 | 661 | 775 | $300,415 | $71,012 |
Total Patients
2,706
Total Services
3,230
Medicare Billing
$271,171
Procedure Codes
60
All Medicare Procedures & Services
60 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 89 | 89 | $35,600 | $11,183 | 31.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 45 | 45 | $112,500 | $10,406 | 9.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 101 | 125 | $25,000 | $9,666 | 38.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 64 | 101 | $15,150 | $5,059 | 33.4% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 23 | 23 | $23,000 | $4,980 | 21.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 49 | 50 | $60,000 | $4,298 | 7.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 41 | 42 | $94,500 | $3,789 | 4.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 28 | 28 | $7,000 | $3,069 | 43.8% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 13 | 13 | $26,000 | $2,252 | 8.7% |
| 76981 | Ultrasound scan of organ tissue for measuring elasticity | Office | 2023 | 15 | 15 | $2,125 | $1,358 | 63.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 54 | 96 | $1,440 | $806.40 | 56.0% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 29 | 29 | $2,900 | $435.40 | 15.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 119 | 119 | $47,600 | $16,339 | 34.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 102 | 121 | $24,200 | $9,817 | 40.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 31 | 31 | $77,500 | $7,422 | 9.6% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 31 | 31 | $31,000 | $6,998 | 22.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 43 | 44 | $11,000 | $5,027 | 45.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 75 | 105 | $15,750 | $4,928 | 31.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 38 | 38 | $85,500 | $4,707 | 5.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 47 | 47 | $56,400 | $4,071 | 7.2% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 13 | 13 | $13,000 | $2,958 | 22.8% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 109 | 116 | $11,600 | $2,257 | 19.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 14 | 14 | $5,600 | $1,647 | 29.4% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 13 | 14 | $1,400 | $511.81 | 36.6% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 19 | 19 | $2,850 | $475.96 | 16.7% |
About Dr. Peter Wayne, MD
Dr. Peter Wayne, MD is a Gastroenterology healthcare provider based in Yonkers, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1831193457.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Wayne, MD has received a total of $33,869 in payments from pharmaceutical and medical device companies, with $999.41 received in 2024. These payments were reported across 426 transactions from 33 companies. The most common payment nature is "Food and Beverage" ($10,651).
As a Medicare-enrolled provider, Wayne has provided services to 2,706 Medicare beneficiaries, totaling 3,230 services with total Medicare billing of $271,171. Data is available for 4 years (2020–2023), covering 60 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Yonkers, NY
- Active Since 06/10/2005
- Last Updated 05/29/2008
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1831193457
Products in Payments
- Mavyret (Drug) $5,004
- ESD - Core Endoscopy (Device) $2,110
- RINVOQ (Biological) $747.52
- STELARA (Biological) $702.42
- Humira (Biological) $653.24
- HUMIRA (Biological) $529.10
- XELJANZ (Drug) $492.71
- Cimzia (Drug) $468.29
- SKYRIZI (Biological) $447.97
- XIFAXAN (Drug) $413.57
- OCALIVA (Drug) $364.17
- Talicia (Drug) $325.81
- ZEPATIER (Drug) $297.30
- ENTYVIO (Biological) $253.87
- Creon (Drug) $249.97
- OCA (Drug) $191.09
- LINZESS (Drug) $190.06
- INJECTAFER (Drug) $188.85
- DIFICID (Drug) $161.64
- Viekira (Drug) $149.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Yonkers
Dr. Jose Lantin, Md, MD
Gastroenterology — Payments: $212,149
Gastroenterology $212,149
Dr. Orest Kozicky, Md, MD
Gastroenterology — Payments: $5,837
Gastroenterology $5,837
Dr. Mitchell Auerbach, Md, MD
Gastroenterology — Payments: $4,695
Gastroenterology $4,695
Beth Schorr-Lesnick, Md, MD
Gastroenterology — Payments: $4,417
Gastroenterology $4,417
David Dicaprio, D.o, D.O
Gastroenterology — Payments: $1,375
Gastroenterology $1,375
Henry Katz, Md, MD
Gastroenterology — Payments: $542.64
Gastroenterology $542.64